The Effects of Sirolimus in Patients With Dilated Cardiomyopathy Infected With Kaposi Sarcoma-associated Virus

This trial is testing whether sirolimus (also known as rapamycin, a drug that suppresses the immune system) can help patients who have dilated cardiomyopathy (an enlarged, weakened heart) and are also infected with KSHV — a virus (Kaposi sarcoma-associated herpesvirus) that may be contributing to the heart disease. **You may be eligible if...** - You are 18 to 70 years old - You have been diagnosed with dilated cardiomyopathy (weak, enlarged heart confirmed by imaging) - You have tested positive for KSHV (a specific herpesvirus) **You may NOT be eligible if...** - You are allergic to rapamycin or its related drugs - Your white blood cell or platelet count is too low - You are pregnant or planning to become pregnant - You have participated in another drug trial within the last 3 months - You have a history of cancer or serious neurological disease Talk to your doctor to see if this trial is right for you.